

hSNF2H (C-16): sc-8760

BACKGROUND

The SWI/SNF complex is involved in the activation of transcription via the remodeling of nucleosome structure in an ATP-dependent manner. Brm (also designated SNF1 or SNF2 α) and Brg-1 (also designated SNF2 or SNF2 β) are the ATPase subunits of the mammalian SWI/SNF complex. Brm, Brg-1, Ini1 (integrase interactor 1, also designated SNF5), BAF155 (also designated SRG3) and BAF170 are thought to comprise the functional core of the SWI/SNF complex. Addition of Ini1, BAF155 and BAF170 to Brg-1 appears to increase remodeling activity. Other complex subunits are thought to play regulatory roles. hSNF2L and hSNF2H both appear to be homologs of *Drosophila* ISWI, a Brm related ATPase that is present in chromatin remodeling complexes other than SWI/SNF, including the NURF (nucleosome remodeling factor).

CHROMOSOMAL LOCATION

Genetic locus: SMARCA5 (human) mapping to 4q31.21; Smarca5 (mouse) mapping to 8 C2.

SOURCE

hSNF2H (C-16) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of hSNF2H of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-8760 X, 200 μ g/0.1 ml.

Blocking peptide available for competition studies, sc-8760 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

hSNF2H (C-16) is recommended for detection of hSNF2H of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

hSNF2H (C-16) is also recommended for detection of hSNF2H in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for hSNF2H siRNA (h): sc-35594, hSNF2H siRNA (m): sc-35595, hSNF2H shRNA Plasmid (h): sc-35594-SH, hSNF2H shRNA Plasmid (m): sc-35595-SH, hSNF2H shRNA (h) Lentiviral Particles: sc-35594-V and hSNF2H shRNA (m) Lentiviral Particles: sc-35595-V.

hSNF2H (C-16) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of hSNF2H: 135 kDa.

Positive Controls: hSNF2H (h): 293T Lysate: sc-113724, K-562 whole cell lysate: sc-2203 or Jurkat whole cell lysate: sc-2204.


RESEARCH USE

For research use only, not for use in diagnostic procedures.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



hSNF2H (C-16): sc-8760. Western blot analysis of hSNF2H expression in K-562 (A) and Jurkat (B) whole cell lysates.



hSNF2H (C-16): sc-8760. Western blot analysis of hSNF2H expression in non-transfected: sc-117752 (A) and human hSNF2H transfected: sc-113724 (B) 293T whole cell lysates.

SELECT PRODUCT CITATIONS

1. Stopka, T., et al. 2003. The ISWI ATPase SNF2H is required for early mouse development. *Proc. Natl. Acad. Sci. USA* 100: 14097-102.
2. Rodriguez, P., et al. 2005. GATA-1 forms distinct activating and repressive complexes in erythroid cells. *EMBO J.* 24: 2354-2366.
3. Rodriguez, P., et al. 2006. Isolation of transcription factor complexes by *in vivo* biotinylation tagging and direct binding to streptavidin beads. *Methods Mol. Biol.* 338: 305-323.
4. Sumegi, J., et al. 2011. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. *Mod. Pathol.* 24: 333-342.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS
Satisfaction
Guaranteed

Try **hSNF2H (D-10): sc-365727**, our highly recommended monoclonal alternative to hSNF2H (C-16).